Last edition
News about "Non-squamous NSCLC treatment"
Innovent Expands Phase 3 MarsLight-11 NSCLC Study
Innovent expands the global phase 3 MarsLight-11 study of IBI363/TAK-928 in immunotherapy-resistant NSCLC to include non-squamous NSCLC patients.
Non-squamous NSCLC Treatment | 29/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members